Please assess the completion status of the following clinical trial:

Trial Title: S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diagnosis of one the following:~  * Stage II-IV gastric cancer~ * Stage IIC-IV ovarian cancer in first complete remission~    * CA 125 normal and stable\*~ * Grade III anaplastic astrocytoma~ * Stage IV (M1) prostate adenocarcinoma~    * No small cell variations~   * No biochemical progression after definitive surgery, defined by the following:~      * Prostate-specific antigen more than 0.4 ng/mL which remains elevated on 2 additional measurements at least 2 weeks apart after prostatectomy~     * Three consecutive rises in PSA, each at least 1 month apart after definitive radiotherapy~   * Must be receiving androgen blockade~   * PSA less than 5 ng/mL and stable\*~* Documented EGFRvIII expression in primary tumor~* Must have received prior surgery and or chemoradiotherapy for disease (except prostate cancer patients) NOTE: \*Stable defined as no increase over 2 measurements at least 28 days apart with the last measurement within the past 28 days~PATIENT CHARACTERISTICS:~Age:~* 80 and under~Performance status:~* Zubrod 0~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic:~* SGOT no greater than 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN~* No hepatitis~Renal:~* Not specified~Other:~* No other malignancy in the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~* No contraindication to receiving sargramostim (GM-CSF) or KLH-based vaccine products~* No autoimmune disease~* HIV negative~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* At least 1 month since prior cytotoxic chemotherapy~* No concurrent chemotherapy~Endocrine therapy:~* See Disease Characteristics~* At least 1 month since prior treatment dose corticosteroids~* No concurrent corticosteroids~Radiotherapy:~* See Disease Characteristics~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics~Other:~* Recovered from all prior therapies~* No concurrent enrollment on other phase I studies~* No other concurrent immune modulators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EGFR vaccine with GMCSF (Type: EXPERIMENTAL): EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m
- EGFR vaccine with KLH (Type: EXPERIMENTAL): EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues